373 related articles for article (PubMed ID: 30384812)
1. Individualized Follow-Up Strategy for Patients with an Indeterminate Response to Initial Therapy for Papillary Thyroid Carcinoma.
Oh HS; Ahn JH; Song E; Han JM; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ
Thyroid; 2019 Feb; 29(2):209-215. PubMed ID: 30384812
[TBL] [Abstract][Full Text] [Related]
2. Thyroglobulin Antibodies as a Prognostic Factor in Papillary Thyroid Carcinoma Patients with Indeterminate Response After Initial Therapy.
Landenberger GMC; de Souza Salerno ML; Golbert L; de Souza Meyer EL
Horm Metab Res; 2021 Feb; 53(2):94-99. PubMed ID: 32886943
[TBL] [Abstract][Full Text] [Related]
3. Clinical Impact of Detectable Antithyroglobulin Antibodies Below the Reference Limit (Borderline) in Patients with Papillary Thyroid Carcinoma with Undetectable Serum Thyroglobulin and Normal Neck Ultrasonography After Ablation: A Prospective Study.
Côrtes MCS; Rosario PW; Oliveira LFF; Calsolari MR
Thyroid; 2018 Feb; 28(2):229-235. PubMed ID: 29325506
[TBL] [Abstract][Full Text] [Related]
4. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
[TBL] [Abstract][Full Text] [Related]
5. Reoperative lymph node dissection for recurrent papillary thyroid cancer and effect on serum thyroglobulin.
Hughes DT; Laird AM; Miller BS; Gauger PG; Doherty GM
Ann Surg Oncol; 2012 Sep; 19(9):2951-7. PubMed ID: 22526913
[TBL] [Abstract][Full Text] [Related]
6. Papillary Thyroid Carcinoma Recurrence: Low Yield of Neck Ultrasound With an Undetectable Serum Thyroglobulin Level.
Epstein S; McEachern R; Khot R; Padia S; Patrie JT; Itri JN
J Ultrasound Med; 2018 Oct; 37(10):2325-2331. PubMed ID: 29498418
[TBL] [Abstract][Full Text] [Related]
7. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
[TBL] [Abstract][Full Text] [Related]
8. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.
Shen FC; Hsieh CJ; Huang IC; Chang YH; Wang PW
Thyroid; 2017 Apr; 27(4):531-536. PubMed ID: 28007013
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems.
Pitoia F; Bueno F; Urciuoli C; Abelleira E; Cross G; Tuttle RM
Thyroid; 2013 Nov; 23(11):1401-7. PubMed ID: 23517313
[TBL] [Abstract][Full Text] [Related]
10. Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment.
Ywata de Carvalho A; Kohler HF; Ywata de Carvalho CCG; Vartanian JG; Kowalski LP
Arch Endocrinol Metab; 2024 Apr; 68():e220506. PubMed ID: 38578436
[TBL] [Abstract][Full Text] [Related]
11. PROGNOSIS OF HIGH-RISK PAPILLARY THYROID CANCER PATIENTS WITH PRE-ABLATION STIMULATED TG <1 NG/ML.
Tian T; Kou Y; Huang R; Liu B
Endocr Pract; 2019 Mar; 25(3):220-225. PubMed ID: 30913010
[TBL] [Abstract][Full Text] [Related]
12. Postoperative stimulated thyroglobulin of less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation.
Rosario PW; Mineiro Filho AF; Prates BS; Silva LC; Calsolari MR
Thyroid; 2012 Nov; 22(11):1140-3. PubMed ID: 23050786
[TBL] [Abstract][Full Text] [Related]
13. Indication for radioactive iodine in patients with papillary thyroid carcinoma without apparent disease after total thyroidectomy but with elevated antithyroglobulin antibodies.
Ramos da Silva F; Rosario PW; Mourão GF
Clin Endocrinol (Oxf); 2022 Jan; 96(1):82-88. PubMed ID: 34323308
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Antithyroglobulin Antibody Concentrations Before and After Ablation with 131I as a Predictor of Structural Disease in Differentiated Thyroid Carcinoma Patients with Undetectable Basal Thyroglobulin and Negative Neck Ultrasonography.
Rosario PW; Carvalho M; Mourão GF; Calsolari MR
Thyroid; 2016 Apr; 26(4):525-31. PubMed ID: 26831821
[TBL] [Abstract][Full Text] [Related]
15. Can the follow-up of patients with papillary thyroid carcinoma of low and intermediate risk and excellent response to initial therapy be simplified using second-generation thyroglobulin assays?
Rosario PW; Mourão GF; Calsolari MR
Clin Endocrinol (Oxf); 2016 Oct; 85(4):596-601. PubMed ID: 26940991
[TBL] [Abstract][Full Text] [Related]
16. Neck Sonography and Suppressed Thyroglobulin Have High Sensitivity for Identifying Recurrent/Persistent Disease in Patients With Low-risk Thyroid Cancer Treated With Total Thyroidectomy and Radioactive Iodine Ablation, Making Stimulated Thyroglobulin Unnecessary.
Domínguez JM; Nilo F; Contreras T; Carmona R; Droppelmann N; González H; Iturrieta V; Tuttle RM
J Ultrasound Med; 2017 Nov; 36(11):2299-2307. PubMed ID: 28543974
[TBL] [Abstract][Full Text] [Related]
17. A Follow-Up Strategy for Patients with an Excellent Response to Initial Therapy for Differentiated Thyroid Carcinoma: Less Is Better.
Jeon MJ; Kim M; Park S; Oh HS; Kim TY; Kim WB; Shong YK; Kim WG
Thyroid; 2018 Feb; 28(2):187-192. PubMed ID: 29179642
[TBL] [Abstract][Full Text] [Related]
18. Sequential changes of serum antithyroglobulin antibody levels are a good predictor of disease activity in thyroglobulin-negative patients with papillary thyroid carcinoma.
Hsieh CJ; Wang PW
Thyroid; 2014 Mar; 24(3):488-93. PubMed ID: 23971786
[TBL] [Abstract][Full Text] [Related]
19. Papillary thyroid cancer: medical management and follow-up.
Kloos RT
Curr Treat Options Oncol; 2005 Jul; 6(4):323-38. PubMed ID: 15967085
[TBL] [Abstract][Full Text] [Related]
20. Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients.
Lamartina L; Montesano T; Trulli F; Attard M; Torlontano M; Bruno R; Meringolo D; Monzani F; Tumino S; Ronga G; Maranghi M; Biffoni M; Filetti S; Durante C
Endocrine; 2016 Nov; 54(2):467-475. PubMed ID: 26668060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
